Key Points
- AtriCure Director Regina Groves sold 5,313 shares for approximately $288,071, reducing her direct ownership by 13.33% to 34,546 shares.
- AtriCure reported quarterly EPS of $0.18 and revenue of $153.6 million, exceeding analysts’ revenue estimate of $151.8 million; management set fiscal 2026 EPS guidance at $0.24–$0.32.
- Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and a $52 target price, while institutional investors own 99.11% of the company’s shares.
AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) Director Regina Groves sold 5,313 shares of the firm's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $54.22, for a total value of $288,070.86. Following the completion of the sale, the director directly owned 34,546 shares in the company, valued at approximately $1,873,084.12. This trade represents a 13.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
AtriCure Price Performance
Shares of ATRC opened at $55.79 on Tuesday. The company has a market cap of $2.84 billion, a P/E ratio of 265.68 and a beta of 1.26. The stock has a fifty day moving average price of $42.88 and a 200 day moving average price of $33.73. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $56.02.
AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The firm had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period last year, the company earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, research analysts forecast that AtriCure, Inc. will post 0.29 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on the stock. Needham & Company LLC lifted their price objective on shares of AtriCure from $45.00 to $64.00 and gave the company a "buy" rating in a research report on Wednesday, September 2nd. Weiss Ratings raised shares of AtriCure from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, August 19th. Piper Sandler upped their target price on shares of AtriCure from $50.00 to $60.00 and gave the stock an "overweight" rating in a research report on Thursday, August 27th. BTIG Research raised their price target on shares of AtriCure from $45.00 to $55.00 and gave the company a "buy" rating in a research note on Monday, August 24th. Finally, Zacks Research cut AtriCure from a "strong-buy" rating to a "hold" rating in a report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $52.00.
Get Our Latest Report on ATRC
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of ATRC. ProShare Advisors LLC raised its stake in shares of AtriCure by 6.6% during the fourth quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company's stock valued at $349,000 after purchasing an additional 543 shares in the last quarter. Allworth Financial LP grew its position in AtriCure by 372.8% in the 2nd quarter. Allworth Financial LP now owns 1,527 shares of the medical device company's stock valued at $43,000 after buying an additional 1,204 shares in the last quarter. Rockefeller Capital Management L.P. grew its position in AtriCure by 43.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 3,983 shares of the medical device company's stock valued at $158,000 after buying an additional 1,205 shares in the last quarter. Comerica Bank grew its position in AtriCure by 121.1% in the 4th quarter. Comerica Bank now owns 2,213 shares of the medical device company's stock valued at $88,000 after buying an additional 1,212 shares in the last quarter. Finally, Harbor Investment Advisory LLC acquired a new position in AtriCure during the 2nd quarter valued at about $40,000. 99.11% of the stock is owned by institutional investors and hedge funds.
AtriCure Company Profile
(
Get Free Report)
AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.
Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
